Peter D Kwong Selected Research

NBD-11021

1/2017

Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter D Kwong Research Topics

Disease

72	Infections 03/2022 - 03/2003
21	COVID-19 05/2022 - 01/2020
12	Human Influenza (Influenza) 01/2022 - 06/2009
8	Malaria 01/2022 - 01/2018
7	Virus Diseases (Viral Diseases) 03/2022 - 05/2013
6	Acquired Immunodeficiency Syndrome (AIDS) 01/2021 - 05/2005
5	Pneumonia (Pneumonitis) 02/2021 - 07/2015
3	Viremia 01/2021 - 09/2015
2	Severe Acute Respiratory Syndrome 02/2021 - 01/2020
2	Edema (Dropsy) 02/2021 - 01/2021
2	Communicable Diseases (Infectious Diseases) 01/2021 - 07/2015
2	Bronchiolitis 01/2020 - 11/2016
2	Paramyxoviridae Infections (Parainfluenza) 11/2018 - 11/2016
2	Neoplasms (Cancer) 10/2017 - 01/2017
2	Respiratory Syncytial Virus Infections 01/2016 - 02/2010
2	Persistent Infection 11/2015 - 01/2015
2	HIV Infections (HIV Infection) 06/2015 - 10/2007
2	Gastroenteritis 01/2012 - 07/2011
1	Coronavirus Infections 01/2022
1	Inflammation (Inflammations) 10/2020
1	Myalgia 10/2019
1	Headache (Headaches) 10/2019
1	Chills 10/2019
1	Autoimmune Diseases (Autoimmune Disease) 01/2019
1	Acute Liver Failure (Fulminant Hepatic Failure) 11/2018
1	Hepatitis B 11/2018
1	Respiratory Tract Diseases (Respiratory Tract Disease) 01/2017
1	Breakthrough Infections 02/2015
1	Vesicular Stomatitis 01/2012
1	Respiratory Tract Infections (Respiratory Tract Infection) 06/2011

Drug/Important Bio-Agent (IBA)

41	VaccinesIBA 01/2022 - 05/2005
38	AntibodiesIBA 03/2022 - 05/2005
18	Broadly Neutralizing AntibodiesIBA 01/2022 - 01/2012
18	Neutralizing AntibodiesIBA 12/2021 - 03/2003
15	EpitopesIBA 03/2022 - 05/2005
14	Glycoproteins (Glycoprotein)IBA 10/2019 - 07/2003
12	Monoclonal AntibodiesIBA 03/2022 - 05/2005
9	Proteins (Proteins, Gene)FDA Link 05/2022 - 05/2012
8	Antiviral Agents (Antivirals)IBA 02/2021 - 11/2008
7	Hemagglutinins (Hemagglutinin)IBA 01/2022 - 09/2015
5	AntigensIBA 10/2020 - 06/2009
3	Fc Receptors (Fc Receptor)IBA 02/2021 - 09/2015
3	Polysaccharides (Glycans)IBA 01/2020 - 11/2016
3	CD4 Antigens (CD4 Antigen)IBA 01/2019 - 10/2007
2	DH1047IBA 01/2022 - 04/2021
2	Single-Domain AntibodiesIBA 03/2021 - 01/2021
2	CytokinesIBA 02/2021 - 01/2021
2	Blocking AntibodiesIBA 02/2021 - 01/2021
2	Immunoglobulin G (IgG)IBA 01/2020 - 01/2012
2	Immunoglobulins (Immunoglobulin)IBA 01/2019 - 09/2015
2	peptide AIBA 01/2018 - 01/2018
2	Peptides (Polypeptides)IBA 01/2018 - 01/2018
2	Influenza Vaccines (Influenza Vaccine)FDA Link 07/2017 - 09/2015
2	env Gene ProductsIBA 01/2016 - 01/2012
2	recombinant soluble CD4IBA 09/2009 - 05/2005
1	SARS-CoV-2 spike proteinIBA 01/2022
1	Angiotensin-Converting Enzyme 2IBA 12/2021
1	keyhole-limpet hemocyanin (keyhole limpet hemocyanin)IBA 03/2021
1	Surface Antigens (Surface Antigen)IBA 01/2021
1	Complement System Proteins (Complement)IBA 01/2021
1	Immunoglobulin M (IgM)IBA 01/2020
1	avian influenza A virus hemagglutininIBA 01/2019
1	Hepatitis B Core AntigensIBA 11/2018
1	Ferritins (Ferritin)IBA 11/2018
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2017
1	Adenosine Triphosphate (ATP)IBA 01/2017
1	InterferonsIBA 01/2017
1	NBD-11021IBA 01/2017
1	LectinsIBA 01/2017
1	DC-specific ICAM-3 grabbing nonintegrin (DC-SIGN)IBA 01/2017
1	Combined VaccinesIBA 12/2016
1	Pharmaceutical PreparationsIBA 04/2015
1	Indicators and Reagents (Reagents)IBA 04/2015
1	Cell Surface ReceptorsIBA 07/2014
1	Tyrosine (L-Tyrosine)FDA Link 05/2014
1	Complementarity Determining Regions (Complementarity Determining Region)IBA 05/2014
1	Blood Group Antigens (Blood Groups)IBA 07/2011
1	motavizumab (Numax)IBA 02/2010
1	Palivizumab FDA Link 02/2010
1	N- (4- chlorophenyl)- N'- (2,2,6,6- tetramethylpiperidin- 4- yl)oxalamideIBA 11/2008
1	ChemokinesIBA 05/2005

Therapy/Procedure

5	Therapeutics 02/2021 - 11/2011
2	Intravenous Administration 01/2022 - 10/2019
1	Immunotherapy 01/2021
1	Liver Transplantation 11/2018
1	Highly Active Antiretroviral Therapy (HAART) 10/2015
1	Aftercare (After-Treatment) 08/2015